EDN1 and chronic kidney disease: Given the evidence for the involvement of ET-1 in the early (inflammatory) pathogenesis of CKD, this SGLT2i-mediated effect might—at least partially—explain the observed effectiveness of this class of drugs in large-scale clinical trials.